ClinicalTrials.gg
RecruitingNCT05302284Updated Dec 18, 2023

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

A Phase 3 interventional study of RC48-ADC and Toripalimab in Urothelial Carcinoma and HER2-expressing, sponsored by RemeGen Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-18.

Sponsored by RemeGen Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing disitamab vedotin in Carcinoma, Transitional Cell — 5 open to participants now, 6 under way, 2 of them phase 3. disitamab vedotin · Carcinoma, Transitional Cell.

Planned enrollment
Largest of 10
452 · median 40
Started
2022
with 2 others
Phase 3
2 of 10
1 open now
Registered
6th of 10
by date
Lead sponsor
4 of 10
RemeGen Co., Ltd.

Among the 10 studies testing disitamab vedotin in Carcinoma, Transitional Cell, this one has the largest planned enrollment, is one of 3 that started in 2022, is one of 2 in phase 3, and was the 6th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

5 of the 10 studies testing disitamab vedotin in Carcinoma, Transitional Cell are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About disitamab vedotin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing disitamab vedotin in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.

Read the detailed description

This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study to evaluate the efficacy and safety of RC48-ADC,a recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate, in Combination With JS001,a PD-1 monoclonal antibody, for the treatment of Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.

03

Conditions studied

  • Urothelial Carcinoma
  • HER2-expressing

Keywords

  • Urothelial Carcinoma
  • HER2-expressing
  • RC48
  • First-Line
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Expected survival ≥12 weeks.
  • Locally advanced unresectable or UC with histopathological confirmation, including UC originating from the renal pelvis, ureters, bladder, or urethra.
  • Participants must not have received prior systemic therapy for locally advanced or metastatic urothelial carcinoma with the following exceptions:

Participants that received chemotherapy with recurrence >6 months from completion of therapy are permitted; Participants that received adjuvant chemotherapy following cystectomy with recurrence >6 months from completion of therapy are permitted.

  • At least one based on version 1.1
  • -expressing status determined by the central laboratory to be IHC 1+, 2+ or 3+.
  • performance status score: 0 or 1.
  • Adequate cardiac, bone marrow, hepatic, renal, and coagulation functions.

Exclusion criteria

Exclusion Criteria:

  • Known to RC48-ADC or Toripalimab or any of its components.
  • History of major surgery within 4 weeks of planned start of trial treatment.
  • Toxicity from a previous treatment has not returned to Grade 0-1.
  • Prior ADCs or /PD-L1 inhibitor therapy.
  • Active central nervous system (CNS) .
  • Known active , active , or (HIV) infection.
  • History of other within the previous 5 years, except for low-risk localized prostate cancer, appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above.
  • Other serious, uncontrolled concomitant diseases that may affect protocol compliance or interpretation of outcomes, including active opportunistic infections or advanced (severe) infections, or uncontrolled diabetes.
  • Active diseases that require systemic therapy over the past 2 years. Replacement therapies (such as thyroxine, insulin, or physiological replacement of due to renal or pituitary deficiency) are allowed.
  • Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
452 participants (estimated)

Study arms

  • Experimental
    RC48-ADC + JS001

    Participants will receive RC48-ADC + JS001 every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

    Drug: RC48-ADC · Drug: Toripalimab

  • Active comparator
    Gemcitabine + cisplatin/carboplatin

    Participants will receive Gemcitabine + cisplatin or carboplatin every 3 weeks (Q3W) for maximum 6 weeks or until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

    Drug: Gemcitabine · Drug: Cisplatin · Drug: Carboplatin

Interventions

  • 2.0 mg/kg IV every 2 weeks

    Also known as: Disitamab Vedotin

  • 3.0 mg/kg IV every 2 weeks

    Also known as: JS001

  • 1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle

  • 70mg/m2 IV infusion on Day 1 of every 3 week cycle

  • AUC=4.5, IV infusion on Day 1 of every 3 week cycle

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS), evaluated by independent review committee

    Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by independent review committee according to the RECIST 1.1 standard.

    Time frame: Up to approximately 3 years

  2. Overall survival (OS)

    Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Objective remission rate (ORR)

    The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed).

    Time frame: Up to approximately 3 years

  2. Progression-free survival (PFS), evaluated by the investigator

    Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

    Time frame: Up to approximately 3 years

  3. Duration of relief (DOR)

    DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death

    Time frame: Up to approximately 3 years

  4. Disease control rate (DCR)

    Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.

    Time frame: Up to approximately 3 years

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.

Of 28 phase 3 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's planned 54 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2022
First posted
Mar 31, 2022
StartActual
Jun 14, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Apr 30, 2028
Last update
Dec 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05302284
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Jun 14, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Dec 18, 2023

Study contacts

Jianmin Fang, PhD
Contact
jianminfang@hotmail.com
+86-010-58075561
Na Su, PhD
study director · RemeGen Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Disitamab vedotin

Start the discussion